Category Archives: Deals

J.P. Morgan: Suits Take San Francisco

By Ben Comer | Published: January 10, 2013
The perennial fat got chewed during the first two days at J.P. Morgan’s annual healthcare conference – buy back stock or raise dividends? – and the usual suspects lurked, but newcomers like Walgreens and not-so-pharma companies like Life Technologies packed the presentation halls and corridors, demonstrating investor and general interest in new ideas, products and [...]
Also posted in Biotech, Events, Global, R&D, Regulatory, Strategy, Technology, healthcare, leadership, pricing | Tagged | Leave a comment

Pharma in the Dell: Working with Academia

By Ben Comer | Published: November 14, 2012
How can the emerging field of data science help to fruitfully translate research and discovery into successful drug development? Academics and pharmaceutical executives at Mount Sinai’s School of Medicine discussed ways to build a bridge across the valley of death, and the growing importance of data across all business areas.
Also posted in Biotech, IP, Meetings, People, R&D, Strategy, Technology, leadership | Tagged , , , , , , | Leave a comment

Merck and Novartis Down in Q3 Financial Reports

By Guest Blogger | Published: October 31, 2012
By Jennifer Markarian Pharmaceutical industry leaders Novartis and Merck—among others—released second-quarter 2012 results showing global sales down in third-quarter 2012, with growth in key pharmaceutical products helping to offset losses due to patent expirations.
Also posted in Global, Guest Blog, leadership | Tagged , , , , | Leave a comment

New Non-Profit Alliance of Big Pharma Firms

By Guest Blogger | Published: September 21, 2012
By Amy Ritter. Ten biopharmaceutical companies announced the formation of a nonprofit organization called TransCelerate BioPharma, the mission of which is to accelerate the development of new medicines by identifying and solving common drug development challenges.
Also posted in Biotech, Guest Blog | Tagged , , , , , , , , , , | Leave a comment

Bristol-Myers Squibb's Summertime Blues

By Ben Comer | Published: August 7, 2012
The sun was shining, savory scents were floating out from the grill, the lemonade was mixed and the table was set. But then dark clouds blew in and settled overhead. Bristol-Myers Squibb’s (BMS) picnic got rained out this summer. One element of the rain out was forecasted long ago; Plavix, the multibillion dollar [...]
Also posted in Advertising, Biotech, FDA, Legal, Marketing, R&D, Regulatory, Safety, Sales, Strategy, compliance, pricing | Tagged , , , , , | Leave a comment